WO2008049657A3 - Verwendung von (meth)acrylat-copolymeren in retard-arzneiformen zur verringerung des einflusses von ethanol auf die wirkstofffreisetzung - Google Patents

Verwendung von (meth)acrylat-copolymeren in retard-arzneiformen zur verringerung des einflusses von ethanol auf die wirkstofffreisetzung Download PDF

Info

Publication number
WO2008049657A3
WO2008049657A3 PCT/EP2007/058100 EP2007058100W WO2008049657A3 WO 2008049657 A3 WO2008049657 A3 WO 2008049657A3 EP 2007058100 W EP2007058100 W EP 2007058100W WO 2008049657 A3 WO2008049657 A3 WO 2008049657A3
Authority
WO
WIPO (PCT)
Prior art keywords
release
active ingredient
meth
influence
acrylate copolymers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/058100
Other languages
English (en)
French (fr)
Other versions
WO2008049657A2 (de
Inventor
Hans-Ulrich Petereit
Brigitte Skalsky
Diego Gallardo
Manfred Assmus
Andreas Gryczke
Wolfgang Weisbrod
Felix Hofmann
Hans Baer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roehm GmbH Darmstadt
Original Assignee
Evonik Roehm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm GmbH filed Critical Evonik Roehm GmbH
Publication of WO2008049657A2 publication Critical patent/WO2008049657A2/de
Publication of WO2008049657A3 publication Critical patent/WO2008049657A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

Die Erfindung betrifft die Verwendung von magensaftunlöslichen (Meth)acrylat- Copolymeren in oralen Retard-Arzneiformen als Matrixbildner für den enthaltenen Wirkstoff zur Veringerung des Effektes der Beschleunigung oder Verlangsamung der Wirkstofffreisetzung durch den Einfluss von Ethanol unter in-vitro Bedingungen.
PCT/EP2007/058100 2006-10-26 2007-08-06 Verwendung von (meth)acrylat-copolymeren in retard-arzneiformen zur verringerung des einflusses von ethanol auf die wirkstofffreisetzung Ceased WO2008049657A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006051020.8 2006-10-26
DE200610051020 DE102006051020A1 (de) 2006-10-26 2006-10-26 Verwendung von (Meth)acrylat-Copolymeren in Retard-Arzneiformen zur Verringerung des Einflusses von Ethanol auf die Wirkstofffreisetzung

Publications (2)

Publication Number Publication Date
WO2008049657A2 WO2008049657A2 (de) 2008-05-02
WO2008049657A3 true WO2008049657A3 (de) 2008-10-30

Family

ID=38521102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/058100 Ceased WO2008049657A2 (de) 2006-10-26 2007-08-06 Verwendung von (meth)acrylat-copolymeren in retard-arzneiformen zur verringerung des einflusses von ethanol auf die wirkstofffreisetzung

Country Status (3)

Country Link
DE (1) DE102006051020A1 (de)
TW (1) TW200833372A (de)
WO (1) WO2008049657A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008286914B2 (en) 2007-08-13 2014-10-02 Ohemo Life Sciences Inc. Abuse resistant drugs, method of use and method of making
MX2011003047A (es) * 2008-09-24 2011-04-14 Evonik Roehm Gmbh Composicion farmaceutica de opioide de liberacion controlada ph dependiente con resistencia contra la influencia de etanol.
JP5453434B2 (ja) * 2008-09-24 2014-03-26 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング エタノールの影響に対する耐性を有するオピオイドではないｐＨ依存の制御放出の医薬組成物
CN104984343B (zh) * 2008-09-24 2019-04-02 赢创罗姆有限公司 耐受乙醇影响的非阿片类药物的pH依赖性受控释放的药物组合物
CN105287434A (zh) * 2009-03-18 2016-02-03 赢创罗姆有限公司 采用含有中性乙烯基聚合物和赋形剂的包衣的具有耐乙醇影响的控释药物组合物
SI2408436T1 (sl) * 2009-03-18 2017-06-30 Evonik Roehm Gmbh Farmacevtski sestavek z nadzorovanim sproščanjem z odpornostjo na vpliv etanola, ki uporablja oplaščenje, ki vsebuje nevtralne vinil polimere in ekscipiente
CN102365083A (zh) * 2009-03-18 2012-02-29 赢创罗姆有限公司 采用包含聚合物混合物和赋形剂的包衣的具有耐乙醇影响的控释药物组合物
CN103002881B (zh) * 2010-05-10 2015-09-02 欧洲凯尔特公司 载有活性剂的颗粒与额外活性剂的组合
AU2011252039B2 (en) 2010-05-10 2014-06-12 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
CA2798884C (en) * 2010-05-10 2016-09-13 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
AU2011370762A1 (en) 2011-06-17 2013-11-14 Evonik Rohm Gmbh Coating composition suitable for pharmaceutical or nutraceutical dosage forms
CN103501767A (zh) 2011-06-17 2014-01-08 赢创罗姆有限公司 适合于药物或营养制品剂型的包衣组合物
BR112013027484A8 (pt) 2011-06-17 2022-07-05 Evonik Roehm Gmbh Composição farmacêutica ou nutracêutica com resistência gástrica, e uso de um polímero de (met)acrilato
WO2014146093A2 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
WO2015071380A1 (en) 2013-11-13 2015-05-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
MX2021010914A (es) 2019-03-11 2021-10-01 Evonik Operations Gmbh Forma de dosificacion que comprende una matriz polimerica.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074033A1 (en) * 2002-02-11 2003-09-12 Pliva-Istrazivacki Institut D.O.O. Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
WO2006079550A2 (en) * 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
WO2006094083A1 (en) * 2005-02-28 2006-09-08 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
WO2007053698A2 (en) * 2005-10-31 2007-05-10 Alza Corporation Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
WO2007085024A2 (en) * 2006-01-21 2007-07-26 Abbott Gmbh & Co. Kg Dosage form and method for the delivery of drugs of abuse
WO2008011595A2 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophobic abuse deterrent delivery system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152414A (en) * 1978-08-18 1979-05-01 Iowa State University Research Foundation, Inc. Combination vaccine for swine dysentery and method of use
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
AU2001273687A1 (en) * 2000-07-10 2002-01-21 Massachusetts Institute Of Technology Method and materials for controlling migration of binder liquid in a powder
DE10058771A1 (de) * 2000-11-27 2002-06-06 Falk Pharma Gmbh Coazervierungsverfahren zur Herstellung von verzögert feisetzenden Arzneimitteln
CA2572491A1 (en) * 2004-07-01 2006-01-12 Gruenenthal Gmbh Oral dosage form safeguarded against abuse

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074033A1 (en) * 2002-02-11 2003-09-12 Pliva-Istrazivacki Institut D.O.O. Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
WO2006079550A2 (en) * 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
WO2006094083A1 (en) * 2005-02-28 2006-09-08 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
WO2007053698A2 (en) * 2005-10-31 2007-05-10 Alza Corporation Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
WO2007085024A2 (en) * 2006-01-21 2007-07-26 Abbott Gmbh & Co. Kg Dosage form and method for the delivery of drugs of abuse
WO2008011595A2 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophobic abuse deterrent delivery system

Also Published As

Publication number Publication date
WO2008049657A2 (de) 2008-05-02
DE102006051020A1 (de) 2008-04-30
TW200833372A (en) 2008-08-16

Similar Documents

Publication Publication Date Title
WO2008049657A3 (de) Verwendung von (meth)acrylat-copolymeren in retard-arzneiformen zur verringerung des einflusses von ethanol auf die wirkstofffreisetzung
WO2010066749A3 (en) Ulipristal acetate tablets
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
PT2043600T (pt) Formulações farmacêuticas para a libertação prolongada de princípio(s) ativo(s), assim como suas aplicações, nomeadamente terapêuticas
WO2006084164A8 (en) Gastric retention and controlled release delivery system
WO2009063222A3 (en) Solid compositions
SI1906939T1 (sl) Uporaba delno nevtraliziranega anionskega kopolimera (met)akrilata kot oplaščenje za izdelavo zdravila, ki sprošča aktivno učinkovino pri znižanih vrednostih pH
WO2009117130A3 (en) Extended release forumulation containing a wax
IL192773A0 (en) Microparticulate pharmaceutical forms resistant to immediate release of the active ingredient in the presence of alcohol
WO2008061226A3 (en) Sustained-release formulations of topiramate
EP3272337A3 (de) Tabletten
WO2008052033A3 (en) Ibuprofen composition
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
WO2009051022A3 (en) Matrix-type pharmaceutical solid preparation
WO2011101866A3 (en) Gastric retention formulation containing baclofen
MY144857A (en) Phamaceutical composition comprising amlodipine and losartan
WO2011053003A3 (en) Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
WO2009068708A8 (es) Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo
WO2008113901A3 (fr) Composition à libération prolongée de lévétiracetam et procédé de préparation.
WO2008005353A3 (en) Immediate-release tablet formulations of a thrombin receptor antagonist
WO2007016284A3 (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form adminstration daily
WO2007099555A3 (en) Pharmaceutical tablet compositions containing irbesartan
WO2008060546A3 (en) Oral formulations
WO2007110765A3 (en) Processes for the preparation of octreotide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07802495

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07802495

Country of ref document: EP

Kind code of ref document: A2